在阿尔茨海默氏病中为认知功能绘制新的药理干预措施:随机临床试验的系统审查
Inmaculada Xu Lou1,2, Jiayue Chen2,3, Kamran Ali4
1International Education College of Zhejiang Chinese Medical University, Hangzhou, China.
Frontiers in pharmacology
|June 19, 2023
概括
新阿尔茨海默病 (AD) 药物试验显示了一些认知改善,但由于研究有限,需要更多的研究. 本综述绘制了阿兹海默症患者的药理疗法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是指老年学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,导致认知能力下降.
- 目前,对阿尔茨海默病缺乏有效的治疗方法.
- 这项研究解决了对新治疗策略的需求.
研究的目的:
- 审查最近对阿尔茨海默病的药理治疗方法.
- 评估这些治疗对认知功能和心理状态的影响.
- 识别新兴的候选药物和治疗方法.
主要方法:
- 2018年至2023年间发表的随机临床试验 (RCT) 的系统审查.
- 搜索了主要的数据库:PubMed,科学网,Scopus和科克兰图书馆.
- 包括17个RCT,重点关注AD认知功能的药理干预措施.
主要成果:
- 研究了几种新型药物,包括马西替尼,甲基酸盐, levetiracetam 和传统的中国配方 (Jiannao Yizhi,Huannao Yicong).
- 大多数试验集中在患有轻度至中度阿尔茨海默病的患者身上.
- 一些研究药物表明对认知功能的潜在益处.
结论:
- 新兴的药理学药剂在改善阿兹海默症患者的认知功能方面表现有前途.
- 数量有限的研究表明,需要进行进一步的广泛研究.
- 进一步的研究对于建立阿尔茨海默病的有效治疗方法至关重要.
相关概念视频
Alzheimer's Disease: Treatment
223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223
Alzheimer's Disease: Overview
532
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
165
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
165
Dementia
143
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
143
Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K


